Marinomed secures financing through successful capital increase
Marinomed Biotech AG (“Company”) has successfully completed the capital increase against cash contribution announced on March 19, 2026. Through the rights offering to existing shareholders (the “Rights Offering”), 33,322 new shares were subscribed for by exercising subscription rights. Shares not subscribed for were subsequently offered in a prospectus-free private placement at a subscription price of EUR 14 per new share. An additional 125,717 new shares were placed within this framework.
A total of 159,039 new shares of the Company were thus issued as part of the capital increase, with final gross proceeds of approximately EUR 2.23 million. The transaction target of gross proceeds for the Company of at least EUR 2 million was therefore even exceeded.
“We are delighted with the successful capital increase. It confirms the strong confidence investors have in our company and secures the financial foundation we need to achieve our planned milestones. This financing will cover our anticipated liquidity requirements and strengthen our position in the ongoing negotiations for the marketing of our flagship products, Budesolv and Tacrosolv,” said Andreas Grassauer, CEO of Marinomed.
The settlement, delivery, and trading of all new shares under the existing ISIN ATMARINOMED6 on the Vienna Stock Exchange is expected to take place on April 20, 2026, subject to registration of the capital increase in the Commercial Register.
Contact
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: pr@marinomed.com
E-Mail: ir@marinomed.com